WO2012074237A3 - Liquid medicine composition including dorzolamide and brimonidine for ophthalmology - Google Patents

Liquid medicine composition including dorzolamide and brimonidine for ophthalmology Download PDF

Info

Publication number
WO2012074237A3
WO2012074237A3 PCT/KR2011/008911 KR2011008911W WO2012074237A3 WO 2012074237 A3 WO2012074237 A3 WO 2012074237A3 KR 2011008911 W KR2011008911 W KR 2011008911W WO 2012074237 A3 WO2012074237 A3 WO 2012074237A3
Authority
WO
WIPO (PCT)
Prior art keywords
brimonidine
ophthalmology
salt
liquid medicine
medicine composition
Prior art date
Application number
PCT/KR2011/008911
Other languages
French (fr)
Korean (ko)
Other versions
WO2012074237A2 (en
Inventor
이상용
이근혁
김진선
최병선
양재식
Original Assignee
한림제약(주)
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 한림제약(주) filed Critical 한림제약(주)
Publication of WO2012074237A2 publication Critical patent/WO2012074237A2/en
Publication of WO2012074237A3 publication Critical patent/WO2012074237A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/382—Heterocyclic compounds having sulfur as a ring hetero atom having six-membered rings, e.g. thioxanthenes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0031—Rectum, anus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/08—Solutions
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

The present invention provides a liquid medicine composition including as active ingredients dorzolamide or a salt thereof, timolol or a salt thereof, and brimonidine or a salt thereof, for ophthalmology, which is stable and non-irritant. More particularly, the present invention provides a liquid medicine composition for ophthalmology comprising: 1-3 w/v% of dorzolamide or the salt thereof; 0.1-1 w/v% of timolol or the salt thereof; 0.1-0.5 w/v% of brimonidine or the salt thereof; 1.0-1.5 w/v% of polyvinylpyrrolidone; 0.2-0.8 w/v% of sodium chloride; 0.3-0.6 w/v% of a buffering agent; a preservative; a pH controlling agent; and water.
PCT/KR2011/008911 2010-12-02 2011-11-22 Liquid medicine composition including dorzolamide and brimonidine for ophthalmology WO2012074237A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
KR1020100121718A KR101119610B1 (en) 2010-12-02 2010-12-02 Opthalmic liquid composition comprising dorzolamide, timolol, and brimonidine
KR10-2010-0121718 2010-12-02

Publications (2)

Publication Number Publication Date
WO2012074237A2 WO2012074237A2 (en) 2012-06-07
WO2012074237A3 true WO2012074237A3 (en) 2012-08-23

Family

ID=46141437

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/KR2011/008911 WO2012074237A2 (en) 2010-12-02 2011-11-22 Liquid medicine composition including dorzolamide and brimonidine for ophthalmology

Country Status (2)

Country Link
KR (1) KR101119610B1 (en)
WO (1) WO2012074237A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA3013583A1 (en) * 2016-02-22 2017-08-31 Santen Pharmaceutical Co., Ltd. Pharmaceutical composition including dorzolamide and brimonidine
US20190134051A1 (en) * 2017-11-06 2019-05-09 Rheostasis, Llc Composition for treating ocular disorders such as macular degeneration, retinopathy and glaucoma
CN111671720A (en) * 2020-06-23 2020-09-18 苏州悦宏生物科技有限公司 Eye drops for relieving intraocular foreign body sensation
EP4230193A1 (en) * 2022-02-22 2023-08-23 Warszawskie Zaklady Farmaceutyczne Polfa S.A. Ophthalmic pharmaceutical composition

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207222A1 (en) * 2006-03-01 2007-09-06 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
US20090048261A1 (en) * 2007-08-17 2009-02-19 Arturo Jimenez Bayardo Pharmaceutical Composition for Treatment of Ocular Hypertension
US20090069345A1 (en) * 2007-09-12 2009-03-12 Arturo Jimenez Bayardo Pharmaceutically Stable Compound Consisting of Timolol, Dorzolamide and Brimonidine
KR20090053892A (en) * 2006-07-25 2009-05-28 오스모티카 코프. Ophthalmic solutions

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20070207222A1 (en) * 2006-03-01 2007-09-06 Tristrata, Inc. Composition and method for topical treatment of tar-responsive dermatological disorders
KR20090053892A (en) * 2006-07-25 2009-05-28 오스모티카 코프. Ophthalmic solutions
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
US20090048261A1 (en) * 2007-08-17 2009-02-19 Arturo Jimenez Bayardo Pharmaceutical Composition for Treatment of Ocular Hypertension
US20090069345A1 (en) * 2007-09-12 2009-03-12 Arturo Jimenez Bayardo Pharmaceutically Stable Compound Consisting of Timolol, Dorzolamide and Brimonidine

Also Published As

Publication number Publication date
KR101119610B1 (en) 2012-03-06
WO2012074237A2 (en) 2012-06-07

Similar Documents

Publication Publication Date Title
NZ602685A (en) Concentrated protein formulations and uses thereof
MX2011011175A (en) High-strength, herbicidal compositions of glyphosate and 2,4-d salts.
WO2014099226A3 (en) Personal cleansing compositions containing zinc amino acid/trimethylglycine halide
AU2011338389A8 (en) Bicyclic compounds as Pim inhibitors
TR201820605T4 (en) Fungicidal composition and method for controlling plant diseases
WO2009080203A3 (en) Aminobenzamide derivatives as useful agents for controlling animal parasites
PH12015502542A1 (en) Stabilized pemetrexed formulation
MX2009003042A (en) Self-preserved aqueous pharmaceutical compositions.
JP2009531457A5 (en)
JO2973B1 (en) Fumarate Salt Of (alphaS, betaR)-6-Bromo-alfa-[2-(dimethylamino)ethyl]-2- Methoxy-alpha-1-naphthalenyl-beta-phenyl-3- Quinolineethanol
GEP20146015B (en) Novel acetylsalicylic acid salts
ES2720954T3 (en) Statin Stabilized Formulations
WO2012074237A3 (en) Liquid medicine composition including dorzolamide and brimonidine for ophthalmology
EP2050444A4 (en) Fatigue-reducing agent
NZ599377A (en) Salts, aqueous liquid compositions containing salts of S-(+)-abscisic acid and methods of their preparation
WO2008009405A3 (en) Novel pyridazine derivatives
WO2010107482A3 (en) Germicidal composition
WO2008102349A3 (en) Terbinafine formulation for iontophoresis
IN2015DN00338A (en)
WO2008073444A3 (en) Phou (perf), a persistence switch involved in persister formation as a drug target for persister bacteria
TN2014000152A1 (en) Sustained-release preparation
WO2008036855A3 (en) Self-preserved aqueous pharmaceutical compositions
UA111145C2 (en) Pharmaceutical composition
BR112012027432A2 (en) pharmaceutical compositions with phosphonium antimicrobial agents
WO2010031248A8 (en) Thiazolium salt compound and the use of treating the protein aging disease

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 11845736

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 11845736

Country of ref document: EP

Kind code of ref document: A2